DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Marizomib is an investigational drug.
There have been 9 clinical trials for Marizomib. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2018.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Glioblastoma, and Multiple Myeloma. The leading clinical trial sponsors are Triphase Research and Development I Corporation, National Cancer Institute (NCI), and European Organisation for Research and Treatment of Cancer - EORTC.
There are two hundred and seventy-five US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Marizomib
|Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma||National Cancer Institute (NCI)||Phase 2|
|A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma||Celgene||Phase 3|
|A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma||European Organisation for Research and Treatment of Cancer - EORTC||Phase 3|
Top disease conditions for Marizomib
Top clinical trial sponsors for Marizomib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Marizomib||Start Trial||Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells||Selecta Biosciences, Inc. (Watertown, MA)||Start Trial|
|Marizomib||Start Trial||Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor||Pharmacyclics LLC (Sunnyvale, CA)||Start Trial|
|Marizomib||Start Trial||Methods and compositions for inhibition of Ras||ARAXES PHARMA LLC (San Diego, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|